Home  /  Resource Library  /  Polatuzumab Vedotin Plus Bendamustine with Rituximab or Obinutuzumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Plus Bendamustine with Rituximab or Obinutuzumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Study

Results of a study investigating polatuzumab vedotin combined with bendamustine and rituximab for relapsed diffuse large b-cell lymphoma.